ZA200101453B

ZA200101453B - Promotion or inhibition of angiogenesis and cardiovascularization.

Promotion or inhibition of angiogenesis and cardiovascularization. Download PDF

Info

Publication number: ZA200101453B
Authority: ZA; South Africa
Prior art keywords: pro216; pro230; pro302; polypeptide; pro302 polypeptide
Prior art date: 1998-09-14

Application number

ZA200101453A

Other languages

English (en)

Inventor

Sherman Fong

Mary E Gerritsen

Audrey Goddard

Austin L Gurney

Kenneth J Hillan

P Mickey Williams

William I Wood

Original Assignee

Genentech Inc

Priority date

1998-09-14

Filing date

2001-02-21

Publication date

2002-02-21

2001-02-21 Application filed by Genentech Inc filed Critical Genentech Inc

2002-02-21 Publication of ZA200101453B publication Critical patent/ZA200101453B/en

Links

230000014399 negative regulation of angiogenesis Effects 0.000 title description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 449
102000004196 processed proteins & peptides Human genes 0.000 claims description 442
229920001184 polypeptide Polymers 0.000 claims description 437
150000007523 nucleic acids Chemical group 0.000 claims description 189
210000004027 cell Anatomy 0.000 claims description 177
108091028043 Nucleic acid sequence Proteins 0.000 claims description 136
238000000034 method Methods 0.000 claims description 136
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 120
108090000623 proteins and genes Proteins 0.000 claims description 114
239000005557 antagonist Substances 0.000 claims description 104
206010028980 Neoplasm Diseases 0.000 claims description 98
230000002491 angiogenic effect Effects 0.000 claims description 91
230000003511 endothelial effect Effects 0.000 claims description 90
208000035475 disorder Diseases 0.000 claims description 87
230000002526 effect on cardiovascular system Effects 0.000 claims description 85
239000000203 mixture Substances 0.000 claims description 74
241000124008 Mammalia Species 0.000 claims description 72
238000011282 treatment Methods 0.000 claims description 68
238000012360 testing method Methods 0.000 claims description 65
102000039446 nucleic acids Human genes 0.000 claims description 63
108020004707 nucleic acids Proteins 0.000 claims description 63
239000000556 agonist Substances 0.000 claims description 62
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 59
208000006029 Cardiomegaly Diseases 0.000 claims description 58
150000001875 compounds Chemical class 0.000 claims description 55
241000282414 Homo sapiens Species 0.000 claims description 53
230000027455 binding Effects 0.000 claims description 50
239000013598 vector Substances 0.000 claims description 46
230000014509 gene expression Effects 0.000 claims description 45
239000000523 sample Substances 0.000 claims description 43
230000000694 effects Effects 0.000 claims description 41
201000011510 cancer Diseases 0.000 claims description 37
239000003795 chemical substances by application Substances 0.000 claims description 37
201000010099 disease Diseases 0.000 claims description 32
230000012010 growth Effects 0.000 claims description 31
210000002889 endothelial cell Anatomy 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 26
208000010125 myocardial infarction Diseases 0.000 claims description 25
230000033115 angiogenesis Effects 0.000 claims description 24
230000015572 biosynthetic process Effects 0.000 claims description 22
230000001177 retroviral effect Effects 0.000 claims description 22
230000035772 mutation Effects 0.000 claims description 20
108010076504 Protein Sorting Signals Proteins 0.000 claims description 19
230000010261 cell growth Effects 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 19
230000002401 inhibitory effect Effects 0.000 claims description 17
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
208000002780 macular degeneration Diseases 0.000 claims description 13
108091034117 Oligonucleotide Proteins 0.000 claims description 12
206010064930 age-related macular degeneration Diseases 0.000 claims description 12
230000036755 cellular response Effects 0.000 claims description 12
230000006698 induction Effects 0.000 claims description 12
239000004037 angiogenesis inhibitor Substances 0.000 claims description 11
229940127089 cytotoxic agent Drugs 0.000 claims description 11
208000014674 injury Diseases 0.000 claims description 11
230000008733 trauma Effects 0.000 claims description 11
210000004962 mammalian cell Anatomy 0.000 claims description 10
239000002245 particle Substances 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 8
101710172711 Structural protein Proteins 0.000 claims description 7
238000001415 gene therapy Methods 0.000 claims description 7
238000002399 angioplasty Methods 0.000 claims description 6
239000013068 control sample Substances 0.000 claims description 6
230000004936 stimulating effect Effects 0.000 claims description 6
230000035409 positive regulation of cell proliferation Effects 0.000 claims description 5
239000002254 cytotoxic agent Substances 0.000 claims description 4
231100000599 cytotoxic agent Toxicity 0.000 claims description 4
238000004806 packaging method and process Methods 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
229940127557 pharmaceutical product Drugs 0.000 claims description 4
230000018448 secretion by cell Effects 0.000 claims description 4
238000009007 Diagnostic Kit Methods 0.000 claims description 3
ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 claims 1
239000000074 antisense oligonucleotide Substances 0.000 claims 1
238000012230 antisense oligonucleotides Methods 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 description 143
108020004414 DNA Proteins 0.000 description 56
210000001519 tissue Anatomy 0.000 description 52
229940024606 amino acid Drugs 0.000 description 51
235000001014 amino acid Nutrition 0.000 description 48
150000001413 amino acids Chemical class 0.000 description 47
241001465754 Metazoa Species 0.000 description 45
238000003556 assay Methods 0.000 description 45
102000004169 proteins and genes Human genes 0.000 description 43
235000018102 proteins Nutrition 0.000 description 41
210000002216 heart Anatomy 0.000 description 38
206010019280 Heart failures Diseases 0.000 description 37
239000012634 fragment Substances 0.000 description 35
125000000539 amino acid group Chemical group 0.000 description 32
239000002773 nucleotide Substances 0.000 description 32
125000003729 nucleotide group Chemical group 0.000 description 32
108060003951 Immunoglobulin Proteins 0.000 description 28
102000018358 immunoglobulin Human genes 0.000 description 28
102000005962 receptors Human genes 0.000 description 26
108020003175 receptors Proteins 0.000 description 26
239000002585 base Substances 0.000 description 25
230000001965 increasing effect Effects 0.000 description 23
239000002299 complementary DNA Substances 0.000 description 22
239000000427 antigen Substances 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
238000006467 substitution reaction Methods 0.000 description 20
240000004808 Saccharomyces cerevisiae Species 0.000 description 19
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
206010007559 Cardiac failure congestive Diseases 0.000 description 16
206010020880 Hypertrophy Diseases 0.000 description 16
238000001727 in vivo Methods 0.000 description 16
108020004999 messenger RNA Proteins 0.000 description 16
241000700159 Rattus Species 0.000 description 15
230000004071 biological effect Effects 0.000 description 15
210000000107 myocyte Anatomy 0.000 description 15
108091033319 polynucleotide Proteins 0.000 description 15
102000040430 polynucleotide Human genes 0.000 description 15
239000002157 polynucleotide Substances 0.000 description 15
230000000747 cardiac effect Effects 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
210000002435 tendon Anatomy 0.000 description 14
108010047041 Complementarity Determining Regions Proteins 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
239000000126 substance Substances 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
102000002045 Endothelin Human genes 0.000 description 12
108050009340 Endothelin Proteins 0.000 description 12
206010020772 Hypertension Diseases 0.000 description 12
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 12
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
238000004590 computer program Methods 0.000 description 12
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 12
230000006870 function Effects 0.000 description 12
239000007787 solid Substances 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
238000013518 transcription Methods 0.000 description 12
230000035897 transcription Effects 0.000 description 12
206010009944 Colon cancer Diseases 0.000 description 11
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
239000002253 acid Substances 0.000 description 11
230000001413 cellular effect Effects 0.000 description 11
-1 endothelin-1. -2 Chemical class 0.000 description 11
239000003623 enhancer Substances 0.000 description 11
238000009396 hybridization Methods 0.000 description 11
229940072221 immunoglobulins Drugs 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
230000004044 response Effects 0.000 description 11
230000002792 vascular Effects 0.000 description 11
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
210000000349 chromosome Anatomy 0.000 description 10
229940079593 drug Drugs 0.000 description 10
230000004927 fusion Effects 0.000 description 10
239000012528 membrane Substances 0.000 description 10
238000011580 nude mouse model Methods 0.000 description 10
239000000047 product Substances 0.000 description 10
238000012216 screening Methods 0.000 description 10
210000004881 tumor cell Anatomy 0.000 description 10
230000002861 ventricular Effects 0.000 description 10
101100137546 Arabidopsis thaliana PRF2 gene Proteins 0.000 description 9
241000282326 Felis catus Species 0.000 description 9
101150004094 PRO2 gene Proteins 0.000 description 9
206010000891 acute myocardial infarction Diseases 0.000 description 9
238000010171 animal model Methods 0.000 description 9
238000013459 approach Methods 0.000 description 9
238000010367 cloning Methods 0.000 description 9
230000006378 damage Effects 0.000 description 9
230000013595 glycosylation Effects 0.000 description 9
238000006206 glycosylation reaction Methods 0.000 description 9
208000019622 heart disease Diseases 0.000 description 9
102000058223 human VEGFA Human genes 0.000 description 9
230000003993 interaction Effects 0.000 description 9
210000003041 ligament Anatomy 0.000 description 9
239000007788 liquid Substances 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
230000008569 process Effects 0.000 description 9
230000029663 wound healing Effects 0.000 description 9
239000005541 ACE inhibitor Substances 0.000 description 8
241000894006 Bacteria Species 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000002759 chromosomal effect Effects 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
230000007547 defect Effects 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000013615 primer Substances 0.000 description 8
230000007017 scission Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
229960000187 tissue plasminogen activator Drugs 0.000 description 8
230000009261 transgenic effect Effects 0.000 description 8
230000014616 translation Effects 0.000 description 8
208000019553 vascular disease Diseases 0.000 description 8
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 7
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 7
108020005544 Antisense RNA Proteins 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
206010029113 Neovascularisation Diseases 0.000 description 7
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 7
102000013275 Somatomedins Human genes 0.000 description 7
108700019146 Transgenes Proteins 0.000 description 7
230000009471 action Effects 0.000 description 7
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
210000000988 bone and bone Anatomy 0.000 description 7
239000003184 complementary RNA Substances 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
238000001514 detection method Methods 0.000 description 7
229940000406 drug candidate Drugs 0.000 description 7
230000006872 improvement Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
230000008506 pathogenesis Effects 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
230000017423 tissue regeneration Effects 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
201000001320 Atherosclerosis Diseases 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
208000020446 Cardiac disease Diseases 0.000 description 6
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
241000700605 Viruses Species 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
230000035508 accumulation Effects 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
206010002906 aortic stenosis Diseases 0.000 description 6
210000001367 artery Anatomy 0.000 description 6
230000008901 benefit Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000036772 blood pressure Effects 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 6
229960000830 captopril Drugs 0.000 description 6
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 6
230000003915 cell function Effects 0.000 description 6
208000029742 colonic neoplasm Diseases 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
230000004069 differentiation Effects 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
230000035876 healing Effects 0.000 description 6
230000000004 hemodynamic effect Effects 0.000 description 6
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 6
230000001969 hypertrophic effect Effects 0.000 description 6
230000001771 impaired effect Effects 0.000 description 6
238000002513 implantation Methods 0.000 description 6
238000007901 in situ hybridization Methods 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
238000013507 mapping Methods 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
230000001737 promoting effect Effects 0.000 description 6
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
238000011160 research Methods 0.000 description 6
150000003384 small molecules Chemical class 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000003556 vascular endothelial cell Anatomy 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
108020004491 Antisense DNA Proteins 0.000 description 5
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 5
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 5
206010061216 Infarction Diseases 0.000 description 5
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010063837 Reperfusion injury Diseases 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
230000004075 alteration Effects 0.000 description 5
239000012491 analyte Substances 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
239000003816 antisense DNA Substances 0.000 description 5
210000000709 aorta Anatomy 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
210000004413 cardiac myocyte Anatomy 0.000 description 5
210000000845 cartilage Anatomy 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
229960004166 diltiazem Drugs 0.000 description 5
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
239000003527 fibrinolytic agent Substances 0.000 description 5
WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 description 5
229950009951 fluprostenol Drugs 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
201000011066 hemangioma Diseases 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
239000002502 liposome Substances 0.000 description 5
239000003226 mitogen Substances 0.000 description 5
230000002107 myocardial effect Effects 0.000 description 5
210000004165 myocardium Anatomy 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
230000008439 repair process Effects 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
238000007423 screening assay Methods 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
241000894007 species Species 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
229960000103 thrombolytic agent Drugs 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000013519 translation Methods 0.000 description 5
241000701161 unidentified adenovirus Species 0.000 description 5
210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
238000005406 washing Methods 0.000 description 5
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 4
229940127291 Calcium channel antagonist Drugs 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
206010010356 Congenital anomaly Diseases 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
101800004490 Endothelin-1 Proteins 0.000 description 4
102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
206010016654 Fibrosis Diseases 0.000 description 4
102100039556 Galectin-4 Human genes 0.000 description 4
101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 4
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 4
108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 4
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
206010067171 Regurgitation Diseases 0.000 description 4
208000017442 Retinal disease Diseases 0.000 description 4
206010038933 Retinopathy of prematurity Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
239000013543 active substance Substances 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
210000001736 capillary Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000002591 computed tomography Methods 0.000 description 4
210000002808 connective tissue Anatomy 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000003205 diastolic effect Effects 0.000 description 4
239000002934 diuretic Substances 0.000 description 4
210000003038 endothelium Anatomy 0.000 description 4
230000004761 fibrosis Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000007943 implant Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000007574 infarction Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
102000028416 insulin-like growth factor binding Human genes 0.000 description 4
108091022911 insulin-like growth factor binding Proteins 0.000 description 4
208000012947 ischemia reperfusion injury Diseases 0.000 description 4
230000000302 ischemic effect Effects 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
229960001597 nifedipine Drugs 0.000 description 4
230000000771 oncological effect Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
238000012453 sprague-dawley rat model Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
230000008685 targeting Effects 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000009466 transformation Effects 0.000 description 4
230000005747 tumor angiogenesis Effects 0.000 description 4
230000005740 tumor formation Effects 0.000 description 4
201000011531 vascular cancer Diseases 0.000 description 4
229960001722 verapamil Drugs 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
206010002329 Aneurysm Diseases 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 3
108010064733 Angiotensins Proteins 0.000 description 3
102000015427 Angiotensins Human genes 0.000 description 3
206010051113 Arterial restenosis Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
241000222120 Candida <Saccharomycetales> Species 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
102100028892 Cardiotrophin-1 Human genes 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
230000004544 DNA amplification Effects 0.000 description 3
102100024746 Dihydrofolate reductase Human genes 0.000 description 3
102400000686 Endothelin-1 Human genes 0.000 description 3
241000282324 Felis Species 0.000 description 3
201000008808 Fibrosarcoma Diseases 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
241000233866 Fungi Species 0.000 description 3
108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
208000010412 Glaucoma Diseases 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
102100021866 Hepatocyte growth factor Human genes 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 3
206010025219 Lymphangioma Diseases 0.000 description 3
206010025282 Lymphoedema Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
101100238304 Mus musculus Morc1 gene Proteins 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
101100407828 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-3 gene Proteins 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
206010038934 Retinopathy proliferative Diseases 0.000 description 3
230000018199 S phase Effects 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
206010047112 Vasculitides Diseases 0.000 description 3
206010047115 Vasculitis Diseases 0.000 description 3
208000008383 Wilms tumor Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000000480 calcium channel blocker Substances 0.000 description 3
150000001720 carbohydrates Chemical group 0.000 description 3
108010041776 cardiotrophin 1 Proteins 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
230000006020 chronic inflammation Effects 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
108020001096 dihydrofolate reductase Proteins 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
239000002308 endothelin receptor antagonist Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
239000012530 fluid Substances 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000004217 heart function Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
229960002003 hydrochlorothiazide Drugs 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000005462 in vivo assay Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
108010046018 leukocyte inhibitory factor Proteins 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
206010025226 lymphangitis Diseases 0.000 description 3
208000002502 lymphedema Diseases 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
210000003470 mitochondria Anatomy 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
201000003142 neovascular glaucoma Diseases 0.000 description 3
210000000944 nerve tissue Anatomy 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000004962 physiological condition Effects 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
229960003712 propranolol Drugs 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000004850 protein–protein interaction Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000007480 spreading Effects 0.000 description 3
238000003892 spreading Methods 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
201000005060 thrombophlebitis Diseases 0.000 description 3
230000008467 tissue growth Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
238000010396 two-hybrid screening Methods 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
206010055031 vascular neoplasm Diseases 0.000 description 3
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
102000013563 Acid Phosphatase Human genes 0.000 description 2
108010051457 Acid Phosphatase Proteins 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
101800001288 Atrial natriuretic factor Proteins 0.000 description 2
102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
241000194108 Bacillus licheniformis Species 0.000 description 2
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000005590 Choroidal Neovascularization Diseases 0.000 description 2
206010060823 Choroidal neovascularisation Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
102000002585 Contractile Proteins Human genes 0.000 description 2
108010068426 Contractile Proteins Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
229940118365 Endothelin receptor antagonist Drugs 0.000 description 2
241000588921 Enterobacteriaceae Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
206010018498 Goitre Diseases 0.000 description 2
208000003807 Graves Disease Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
208000012766 Growth delay Diseases 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
241000235649 Kluyveromyces Species 0.000 description 2
244000285963 Kluyveromyces fragilis Species 0.000 description 2
241001138401 Kluyveromyces lactis Species 0.000 description 2
DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
108010007859 Lisinopril Proteins 0.000 description 2
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
230000027311 M phase Effects 0.000 description 2
208000006395 Meigs Syndrome Diseases 0.000 description 2
206010027139 Meigs' syndrome Diseases 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 2
102000016349 Myosin Light Chains Human genes 0.000 description 2
108010067385 Myosin Light Chains Proteins 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
241000282520 Papio Species 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
208000005228 Pericardial Effusion Diseases 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
208000002151 Pleural effusion Diseases 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
241000607720 Serratia Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
108010023197 Streptokinase Proteins 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
241000282887 Suidae Species 0.000 description 2
102100031372 Thymidine phosphorylase Human genes 0.000 description 2
108700023160 Thymidine phosphorylases Proteins 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
229960000571 acetazolamide Drugs 0.000 description 2
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
208000012998 acute renal failure Diseases 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
108010056243 alanylalanine Proteins 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
229940127088 antihypertensive drug Drugs 0.000 description 2
210000000702 aorta abdominal Anatomy 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
229960002274 atenolol Drugs 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
229960004530 benazepril Drugs 0.000 description 2
NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 2
229960001541 benzthiazide Drugs 0.000 description 2
102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
229960004324 betaxolol Drugs 0.000 description 2
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229960001222 carteolol Drugs 0.000 description 2
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
229960004195 carvedilol Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
229960002155 chlorothiazide Drugs 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000000536 complexating effect Effects 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000002316 cosmetic surgery Methods 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
208000012106 cystic neoplasm Diseases 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
101150018266 degP gene Proteins 0.000 description 2
238000013461 design Methods 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
229960005081 diclofenamide Drugs 0.000 description 2
GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 2
230000029087 digestion Effects 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
239000000539 dimer Substances 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
201000003914 endometrial carcinoma Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
229960002490 fosinopril Drugs 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
239000011521 glass Substances 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
201000010536 head and neck cancer Diseases 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
229960004569 indapamide Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000000297 inotrophic effect Effects 0.000 description 2
239000004041 inotropic agent Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000010354 integration Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
229960002394 lisinopril Drugs 0.000 description 2
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000007726 management method Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960002237 metoprolol Drugs 0.000 description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
239000003607 modifier Substances 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
210000003365 myofibril Anatomy 0.000 description 2
229960004255 nadolol Drugs 0.000 description 2
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229960001783 nicardipine Drugs 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
101150093139 ompT gene Proteins 0.000 description 2
230000008520 organization Effects 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229960002035 penbutolol Drugs 0.000 description 2
KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
208000008494 pericarditis Diseases 0.000 description 2
208000027232 peripheral nervous system disease Diseases 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
101150009573 phoA gene Proteins 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
229960001455 quinapril Drugs 0.000 description 2
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
229960003401 ramipril Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 2
230000010076 replication Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000037390 scarring Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000009987 spinning Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
208000017572 squamous cell neoplasm Diseases 0.000 description 2
238000010186 staining Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
229960005202 streptokinase Drugs 0.000 description 2
210000002820 sympathetic nervous system Anatomy 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
229960004605 timolol Drugs 0.000 description 2
230000009772 tissue formation Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
230000008728 vascular permeability Effects 0.000 description 2
230000006442 vascular tone Effects 0.000 description 2
230000004862 vasculogenesis Effects 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
INAPMGSXUVUWAF-UHFFFAOYSA-L (2,3,4,5,6-pentahydroxycyclohexyl) phosphate Chemical compound OC1C(O)C(O)C(OP([O-])([O-])=O)C(O)C1O INAPMGSXUVUWAF-UHFFFAOYSA-L 0.000 description 1
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000589155 Agrobacterium tumefaciens Species 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102100022987 Angiogenin Human genes 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010002961 Aplasia Diseases 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 1
FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
241000351920 Aspergillus nidulans Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
241000969130 Atthis Species 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
241000713842 Avian sarcoma virus Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
102000013602 Cardiac Myosins Human genes 0.000 description 1
108010051609 Cardiac Myosins Proteins 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
206010007710 Cartilage injury Diseases 0.000 description 1
208000003163 Cavernous Hemangioma Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
201000005262 Chondroma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
208000003044 Closed Fractures Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
201000000057 Coronary Stenosis Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000012624 DNA alkylating agent Substances 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000018672 Dilatation Diseases 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
101710202200 Endolysin A Proteins 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
102000013128 Endothelin B Receptor Human genes 0.000 description 1
108010090557 Endothelin B Receptor Proteins 0.000 description 1
102000010180 Endothelin receptor Human genes 0.000 description 1
108050001739 Endothelin receptor Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588698 Erwinia Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
229930189413 Esperamicin Natural products 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
240000006570 Euonymus japonicus Species 0.000 description 1
235000016796 Euonymus japonicus Nutrition 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
230000037057 G1 phase arrest Effects 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
201000005618 Glomus Tumor Diseases 0.000 description 1
KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
102000030595 Glucokinase Human genes 0.000 description 1
108010021582 Glucokinase Proteins 0.000 description 1
102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
241001149669 Hanseniaspora Species 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
208000002125 Hemangioendothelioma Diseases 0.000 description 1
208000006050 Hemangiopericytoma Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
241000481961 Lachancea thermotolerans Species 0.000 description 1
241000235651 Lachancea waltii Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010065433 Ligament rupture Diseases 0.000 description 1
208000018501 Lymphatic disease Diseases 0.000 description 1
241000282553 Macaca Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100219978 Mus musculus Ccn2 gene Proteins 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
241000221961 Neurospora crassa Species 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108020003217 Nuclear RNA Proteins 0.000 description 1
102000043141 Nuclear RNA Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
240000005373 Panax quinquefolius Species 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
240000002834 Paulownia tomentosa Species 0.000 description 1
235000010678 Paulownia tomentosa Nutrition 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
241000228143 Penicillium Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
206010048734 Phakomatosis Diseases 0.000 description 1
JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
102000001105 Phosphofructokinases Human genes 0.000 description 1
108010069341 Phosphofructokinases Proteins 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
108010001441 Phosphopeptides Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
208000034541 Rare lymphatic malformation Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241000223252 Rhodotorula Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
241000311088 Schwanniomyces Species 0.000 description 1
241001123650 Schwanniomyces occidentalis Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
241000607768 Shigella Species 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
206010043189 Telangiectasia Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
241001149964 Tolypocladium Species 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
241000223259 Trichoderma Species 0.000 description 1
241000009298 Trigla lyra Species 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
102000004987 Troponin T Human genes 0.000 description 1
108090001108 Troponin T Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
244000000188 Vaccinium ovalifolium Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010054880 Vascular insufficiency Diseases 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
206010047295 Ventricular hypertrophy Diseases 0.000 description 1
241000863480 Vinca Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
241000235013 Yarrowia Species 0.000 description 1
HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
108010072788 angiogenin Proteins 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002236 anti-hypertrophic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
238000013096 assay test Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
201000004914 benign vascular tumor Diseases 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
210000001043 capillary endothelial cell Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000003548 cardiotrophic effect Effects 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
229930188550 carminomycin Natural products 0.000 description 1
XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
229950001725 carubicin Drugs 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003200 chromosome mapping Methods 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
210000004953 colonic tissue Anatomy 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
201000006617 congenital myasthenic syndrome 21 Diseases 0.000 description 1
201000006625 congenital myasthenic syndrome 5 Diseases 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
108700029428 des-aspartate-angiotensin I Proteins 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
229960001066 disopyramide Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
231100001129 embryonic lethality Toxicity 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
210000001174 endocardium Anatomy 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
201000006828 endometrial hyperplasia Diseases 0.000 description 1
230000002616 endonucleolytic effect Effects 0.000 description 1
230000008753 endothelial function Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
108060003196 globin Proteins 0.000 description 1
102000018146 globin Human genes 0.000 description 1
230000006377 glucose transport Effects 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
210000001308 heart ventricle Anatomy 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
102000047612 human CCN2 Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
101150020087 ilvG gene Proteins 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000001788 irregular Effects 0.000 description 1
108010078274 isoleucylvaline Proteins 0.000 description 1
229940090046 jet injector Drugs 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
201000005264 laryngeal carcinoma Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004523 ligament cell Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
201000002250 liver carcinoma Diseases 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
230000036244 malformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
206010063344 microscopic polyangiitis Diseases 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000037230 mobility Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001016 myotrophic effect Effects 0.000 description 1
210000001087 myotubule Anatomy 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
229950011093 onapristone Drugs 0.000 description 1
201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
238000004091 panning Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
229920002714 polyornithine Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000026341 positive regulation of angiogenesis Effects 0.000 description 1
230000030114 positive regulation of endothelial cell proliferation Effects 0.000 description 1
230000017363 positive regulation of growth Effects 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000036316 preload Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
201000003804 salivary gland carcinoma Diseases 0.000 description 1
239000004576 sand Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
230000004905 short-term response Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000000527 sonication Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
208000001644 thecoma Diseases 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
108010078580 tyrosylleucine Proteins 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
208000023577 vascular insufficiency disease Diseases 0.000 description 1
230000025102 vascular smooth muscle contraction Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
208000037997 venous disease Diseases 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1